Program 2023
DAY 1
Wednesday, November 22nd 2023
9h30
Registration & Welcome coffee
10h00
Welcome Address
10h05
Opening lectures
- Lima & Mexico room
Chaired by Daniel Larocque, Sanofi
CEPI's approach to vaccine libraries and rapid response platforms - an integral part to its 100 Days Mission
Martina Ochs
Project Leader
CEPI, Norway
Title to be defined
Sofonias Kifle Tessema
Program lead for pathogen genomics
Africa CDC, Ethiopia
Trained immunity: from pathophysiology to therapeutic target
Mihai Netea
Head of the division of Experimental Medicine
Radboud University Medical Center, Netherlands
11h35
France2030 initiatives
- Lima & Mexico room
Accelerating innovation in the field of emerging diseases: the “Biocluster Français pour l'Innovation en Infectiologie (BCF2I)” project
Bruno Lina
Head of Department
Laboratoire de Virologie, Centre national de référence virus des infections respiratoires
& Centre national de référence entérovirus et parechovirus, France
Developing innovative therapies to cure hepatitis B virus infections: from basic science to clinical applications
Fabien Zoulim
Head of the Hepatology Department
Hospices Civils de Lyon & Head of the Viral Hepatitis Research Laboratory - INSERM Unit 1052 - France
12h15
Lunch - Poster presentation - B2B - Exhibition Hall
14h00
Track 1: Alternatives to current antibiotics
- Lima & Mexico room
Chaired by Sébastien Coyne, Aurobac Therapeutics and Ana Antunes, MabDesign
Challenges of phage therapy in 2023: shared insights from key French private and public players
Frédéric Laurent
Co-principal investigator
Hospices Civils de Lyon,
Centre International de Recherche en Infectiologie Inserm U1111-UMR CNRS 5308,
ISPB Lyon - Université Lyon 1, France
Cindy Fèvre
Scientific director
Phaxiam, France
In situ targeted mutagenesis of gut bacteria
David Bikard
Head of lab
Pasteur Institute, France
Founder
Eligo Bioscience - France
Incentivizing Novelty in Antibiotic Development
Gosia Majewska
Health and industrial organization economist
ESSEC Business School, France
ENABLE-2: A European Antibacterial Drug Discovery Platform
Anders Karlén
Project coordinator
ENABLE-2
Head of the Department of Medicinal Chemistry
Uppsala University, Sweden
PanHunter - an all-in-one omics data analysis platform
Erik Schliep
Product Manager
Evotec, France
15h40
Coffee break - B2B - Exhibition Hall - Poster presentation
16h20
Track 2: Immunotherapies
- Lima room
Chaired by Geneviève Inchauspé, Transgene
Transcriptional signatures reveal the immune response underlying progression and pathogenesis in tuberculosis
Anne O'Garra
Principal Group Leader
Francis Crick Institute, UK
Monoclonal antibodies for prolonged Covid-19 protection in immunocompromised individuals
Cécile Artaud
Therapeutic Area Medical Lead
AstraZeneca, France
Life saving stem cell therapy for septic shock and ARDS
Julie Hutin
Co Founder and CEO
StemInov, France
Securing the supply chain for vaccine adjuvants in the future
Dennis Christensen
Head of Global R&D
Croda, Danmark
Promega: A Partner for Multidisciplinary Infectious Disease Research and Development
Aymeric Morlé
Custom/OEM specialist
Promega
Accelerating drug discovery using advanced protein and an-tibody development platforms
Yu-Chih Lin
Technical Specialist
Sino Biological, Germany
16h20
Workshop
- Mexico room
Translational in vivo imaging for anti-infectious diseases treatment and diagnosis follow up by PASREL-Imagerie
Ali Aït-Ikhlef
Business Development Manager
PASREL-Imagerie
Benoît Delache
R&D engineer in animal experimentation
PASREL-Imagerie
Julien Lemaitre
Clinical veterinarian and Immunologist
PASREL-Imagerie
17h20
Breakthrough Innovation session
- Mexico room
Chaired by Mélanie Denizot, Lyonbiopôle
System serology approach on COVID-19 patients' sera reveal specific immune pattern in the heterogeneous population: The COVIDAuRA study
Carla Saade
Phd student
Hospices Civils de Lyon and Centre International de Recherche, France
Fully automated workflow for cytometry data analysis: Evaluating the effects of adjuvant candidates on memory B and T cells in a phase I clinical trial.
Julien Nourikyan
Business Development and Partnerships Manager
Altrabio, France
Limitations of threshold-based decisions in Disease X vaccine clinical trials
Julien Flaig
Epidemiological and health economic simulation modeling
Epimod, France
18h00
Poster presentation - Exhibition Hall - Wine & Cheese
DAY 2
Thursday, November 23nd 2023
9h00
Welcome coffee
9h30
Keynote lectures
- Lima & Mexico room
Chaired by Daniel Larocque, Sanofi
Opportunities and Challenges of AI for Infectious Disease Vaccines and Therapeutics
Saranya Sridhar
Global Head of Clinical Franchise for the mRNA Center and Head of Translational Medicine
Sanofi, United Kingdom
10h30
Coffee break - B2B - Exhibition Hall - Poster presentation
11h00
Track 3: Diagnostic, prognostic and clinical biomarkers
- Lima room
Chaired by Jean François Llitjos, bioMérieux
Biomarkers and AI to develop personalised medicine in sepsis.
Anthony Gordon
Chair in Anaesthesia and Critical Care, NIHR Research Professor & Senior Investigator
Imperial College London, United Kingdom
Endocan, a novel biomarker for pneumonia
Philippe Lassale
Founder
Biothelis, France
Advancing anti-viral and vaccine research with Revvity's fluorescent assays
Mathis Laffenetre
LifeScience Product Leader
Revvity, France
A unique solution for antigens that cannot be detected with classical ELISA in medical diagnostic applications: example for inclusion in clinical trial on long COVID.
Hervé Perron
Chief Scientific Officer
GeNeuro SA, Switzerland
11h00
Roundtable: EU and international initiatives supporting the value chain of countermeasures against infectious diseases from research to access
- Mexico room
Animated by Nadia Khelef, National Acceleration Strategy Emerging Infectious Diseases and CBRN Threats
Marta Tufet Bayona
Head of Policy
GAVI, Switzerland
Anh Wartel
Deputy Director General / Head
IVI Europe Regional Office (IERO) - Sweden
Bangin Brim
Policy Officer Health Threats
European Commission - European Health Emergency Preparedness and Response Authority (HERA), Belgium
Tek-Ang Lim
Scientific officer
Innovative Health Initiative (IHI) - Belgium
12h00
Lunch - Poster presentation - B2B - Exhibition Hall
14h00
Track 3: Diagnostic, prognostic and clinical biomarkers
- Lima room
Chaired by Cyril Guyard, Bioaster
Identification by proteomics of infection markers in the skin: application to a direct diagnosis of Lyme borreliosis
Nathalie Boulanger
Medical entomologist & Research group leader
Université de Strasbourg, France
Strategic Partnerships to Address Diagnostic Unmet Needs in Low- and Middle-Income Countries
Philippe Leissner
Head of R&D Diagnostic Programme
BIOASTER, France
Immune profiling of COVID-19 mRNA vaccines in immunocompromised patients
Arnaud Didierlaurent
Professor at the Faculty of Medicine
University of Geneva, Switzerland
14h00
Breakthrough Innovation session
- Mexico room
Chaired by Fabienne Venet, Hospices Civils de Lyon and Mélanie Denizot, Lyonbiopôle
GlycoFlu, a first-in-class synthetic multivalent sialoside compound with antiviral activity to prevent or treat infections by Influenza viruses
Aurélie Juhem
Chief Executive Officer
AIS biotech, France
Neutralizing and Enhancing Monoclonal Antibodies in SARS-CoV-2 Convalescent Patients: Lessons from Early Variant Infection and Impact on Shaping Emerging Variants
Frédéric Coutant
Associate Professor in Immunology
Hospices Civils of Lyon, France
Inhalable Nanofitin as new therapeutic for direct application in respiratory tract
Sébastien Viollet
Scientist
Affilogic, France
New rapid detection of beta-lactamase producing bacteria using fluorogenic probes
Didier Filopon
R&D projects manager
Molsid, France
Recombinant multimeric spike proteins: A promising vaccine against COVID-19
Marianne Figl
Study Director
Voxcan, France
15h00
Coffee break - B2B - Exhibition Hall - Poster presentation
15h30
Track 4: Innovative vaccines
- Lima & Mexico room
Chaired by Sherif Abouelhadid, London school of Hygiene & Tropical Medicine and Lionel Cupillard, Boehringer Ingelheim Animal Health
Evaluation of vaccination strategies against avian influenza in poultry production networks: comparison of the EVACS tool application in several countries
Claire Hautefeuille
Veterinary & epidemiologist
CIRAD/ UMR Astre, France
Current strategic approaches in the evaluation of vaccines as complementary tools for prevention and control of HPAI
Teshome Mebatsion
Executive Director, Viral Disease Research
Boehringer Ingelheim Santé Animale, France
Multivalent pneumococcal conjugate vaccines: trade-offs of an arms race
Anthony Scott
Epidemiologist
LSHTM, London
KEMRI-Wellcome Trust, Kenya
Recent advancements in the glycoconjugate vaccines field
Francesco Berti
Senior Director
GSK Vaccines, Italy
Clinical update of OVX836, a novel Universal Type A influenza vaccine candidate
Florence Nicolas
Chief Development Officer and Co-Founder
Osivax, France
17h10
Announcement of next year edition
17h20
